Current and Future Landscape of RNA-Based Drugs and Impact of COVID-19 Vaccines Success

This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.

Scope

This 42-page report gives important, expert insight that you won’t find in any other source. 13 curated figures throughout the report illustrate major points and trends relating to RNA-Based drugs and the impact of COVID-19. This report is required reading for:

• Investors that want to understand the current and future RNA-Based drug trends, as well as identifying companies to invest in.
• Companies that are interesting in identifying the current landscape for RNA-Based drugs, as well as the forecast future landscape.
• Large companies with investment groups or BD teams looking to see which companies are predicted to lead the RNA-Based drug landscape in the near and far future.
• Small and medium pharma who want to focus their drug portfolio on future trends regarding RNA technology, and are looking for partnership opportunities.

Reasons to Buy

• Insights on RNA-Based Drug Approval trends
• Insights on active companies with RNA-Based drugs
• Insights on RNA-Based drugs by development stage
• Insights on deals involving RNA-Based drugs
• Insights on RNA-Based drug clinical trial trends
• Insights on RNA-Based forecast sale values
• Insights on major upcoming RNA-Based Drug launches